A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

NCT03758417 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

123

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated early due to a strategic realignment of the sponsor's business plan, not related to safety, efficacy, or data integrity concerns.

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL: LCAR-B38M CAR-T Cell

Sponsor

Nanjing Legend Biotech Co.

Collaborators

[object Object]